GleamWall
中文EN

BIXT BIOXYTRAN, INC

Pharmaceutical Preparations · OTC · SEC CIK 1445815 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.2%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,453.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,582.1%
Debt / equity—
Current ratio0.03x
Interest coverage-25.47x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-1,092.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$454,000$112,337
SG&A expense$648,229$1.17M
Operating income-$1.84M-$2.22M
Interest expense$134,314$84,240
Pretax income-$2.12M-$2.38M
Net income-$2.12M-$2.37M
EPS (basic)-0.02-0.02
EPS (diluted)-0.02-0.02
Weighted avg. shares (diluted)91.84M138.60M
Banking
Deposits$111,547—
Balance sheet
Cash & equivalents$509,914$5,154
Current assets$513,465$5,154
Intangibles$145,087$133,540
Total assets$658,552$138,694
Current liabilities$3.25M$1.93M
Short-term debt—$48,000
Total liabilities$3.25M$1.93M
Shareholders' equity-$2.59M-$1.79M
Shares outstanding108.15M86.78M
Cash flow statement
Operating cash flow-$526,455-$381,316
Investing cash flow-$23,091-$28,194
Financing cash flow$1.05M$388,578
Stock-based compensation$197,376$634,025

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.